El Guerrab A[au] - Search Results

Year	Number of Results
2011	1
2015	1
2016	1
2017	3
2019	1
2020	1
2024	0

1

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.

El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. El Guerrab A, et al. Sci Rep. 2020 Apr 14;10(1):6367. doi: 10.1038/s41598-020-63310-2. Sci Rep. 2020. PMID: 32286420 Free PMC article.

2

Quantification of hypoxia-related gene expression as a potential approach for clinical outcome prediction in breast cancer.

El Guerrab A, Cayre A, Kwiatkowski F, Privat M, Rossignol JM, Rossignol F, Penault-Llorca F, Bignon YJ. El Guerrab A, et al. PLoS One. 2017 Apr 21;12(4):e0175960. doi: 10.1371/journal.pone.0175960. eCollection 2017. PLoS One. 2017. PMID: 28430808 Free PMC article.

3

Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception.

Ferrier J, Bayet-Robert M, Dalmann R, El Guerrab A, Aissouni Y, Graveron-Demilly D, Chalus M, Pinguet J, Eschalier A, Richard D, Daulhac L, Marchand F, Balayssac D. Ferrier J, et al. Among authors: el guerrab a. J Neurosci. 2015 Dec 16;35(50):16418-30. doi: 10.1523/JNEUROSCI.1537-15.2015. J Neurosci. 2015. PMID: 26674867 Free PMC article.

4

Acid-Sensing Ion Channel 1a in the amygdala is involved in pain and anxiety-related behaviours associated with arthritis.

Aissouni Y, El Guerrab A, Hamieh AM, Ferrier J, Chalus M, Lemaire D, Grégoire S, Etienne M, Eschalier A, Ardid D, Lingueglia E, Marchand F. Aissouni Y, et al. Among authors: el guerrab a. Sci Rep. 2017 Mar 2;7:43617. doi: 10.1038/srep43617. Sci Rep. 2017. PMID: 28321113 Free PMC article.

5

Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.

El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. El Guerrab A, et al. Mol Carcinog. 2017 May;56(5):1383-1394. doi: 10.1002/mc.22596. Epub 2017 Mar 6. Mol Carcinog. 2017. PMID: 27864890

6

Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.

Yakhni M, Briat A, El Guerrab A, Furtado L, Kwiatkowski F, Miot-Noirault E, Cachin F, Penault-Llorca F, Radosevic-Robin N. Yakhni M, et al. Among authors: el guerrab a. Am J Cancer Res. 2019 May 1;9(5):1043-1060. eCollection 2019. Am J Cancer Res. 2019. PMID: 31218111 Free PMC article.

7

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.

El Guerrab A, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. El Guerrab A, et al. Oncotarget. 2016 Nov 8;7(45):73618-73637. doi: 10.18632/oncotarget.12037. Oncotarget. 2016. PMID: 27655662 Free PMC article.

8

Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.

El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, Bignon YJ. El Guerrab A, et al. PLoS One. 2011;6(9):e25080. doi: 10.1371/journal.pone.0025080. Epub 2011 Sep 22. PLoS One. 2011. PMID: 21966417 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year